{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:56:55Z","timestamp":1789660615042,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81130030"],"award-info":[{"award-number":["81130030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81000694"],"award-info":[{"award-number":["81000694"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jdermsci.2024.09.003","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T05:09:34Z","timestamp":1726636174000},"page":"24-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Serum inflammatory biomarkers associated with disease severity and response to dupilumab treatment in bullous pemphigoid: A cluster analysis"],"prefix":"10.1016","volume":"116","author":[{"given":"Jiaqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9863","key":"10.1016\/j.jdermsci.2024.09.003_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2024.09.003_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev. Pathol."},{"issue":"1","key":"10.1016\/j.jdermsci.2024.09.003_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","article-title":"Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management","volume":"54","author":"Amber","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jdermsci.2024.09.003_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jdermsci.2024.09.003_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/ced\/llae067","article-title":"Efficacy of omalizumab for the treatment of bullous pemphigoid. Spanish multicenter real-world experience","author":"Aguado V\u00e1zquez","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.09.003_bib6","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients","author":"Chebani","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.jdermsci.2024.09.003_bib7","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjd.16553","article-title":"Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score","volume":"179","author":"Holtsche","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.jdermsci.2024.09.003_bib8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archderm.136.2.174","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid","volume":"136","author":"Schmidt","year":"2000","journal-title":"Arch. Dermatol."},{"issue":"8","key":"10.1016\/j.jdermsci.2024.09.003_bib9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/jdv.18128","article-title":"Mapping ethical and social aspects of biomarker research and its application in atopic dermatitis and psoriasis: a systematic review of reason","volume":"36","author":"Fritzsche","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.jdermsci.2024.09.003_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaci.2021.06.029","article-title":"Unraveling heterogeneity in pediatric atopic dermatitis: identification of serum biomarker based patient clusters","volume":"149","author":"Bakker","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jdermsci.2024.09.003_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2020.04.062","article-title":"Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers","volume":"147","author":"Bakker","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.jdermsci.2024.09.003_bib12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2020.10.094","article-title":"CCL20 in psoriasis: a potential biomarker of disease severity, inflammation, and impaired vascular health","volume":"84","author":"Elnabawi","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.jdermsci.2024.09.003_bib13","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.autrev.2019.03.009","article-title":"Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid","volume":"18","author":"Kowalski","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.jdermsci.2024.09.003_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1365-2133.2006.07601.x","article-title":"Serum chemokine profile in patients with bullous pemphigoid","volume":"156","author":"Nakashima","year":"2007","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2024.09.003_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"issue":"23","key":"10.1016\/j.jdermsci.2024.09.003_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316786","article-title":"From molecular insights to clinical perspectives in drug-associated bullous pemphigoid","volume":"24","author":"de Nicolas-Ruanes","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.jdermsci.2024.09.003_bib17","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.jdermsci.2024.09.003_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol."},{"issue":"10","key":"10.1016\/j.jdermsci.2024.09.003_bib19","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.jdermsci.2024.09.003_bib20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/bjd.20593","article-title":"International multicentre observational study to assess the efficacy and safety of a 0\u00b75 mg kg(-1) per day starting dose of oral corticosteroids to treat bullous pemphigoid","volume":"185","author":"H\u00e9bert","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.jdermsci.2024.09.003_bib21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1365-2230.2001.00838.x","article-title":"Minocycline as a therapeutic option in bullous pemphigoid","volume":"26","author":"Loo","year":"2001","journal-title":"Clin. Exp. Dermatol."},{"issue":"23","key":"10.1016\/j.jdermsci.2024.09.003_bib22","doi-asserted-by":"crossref","first-page":"8267","DOI":"10.1021\/acs.analchem.2c00503","article-title":"Adaptive box-cox transformation: a highly flexible feature-specific data transformation to improve metabolomic data normality for better statistical analysis","volume":"94","author":"Yu","year":"2022","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jdermsci.2024.09.003_bib23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ebiom.2018.12.054","article-title":"Development and validation of an immune gene-set based Prognostic signature in ovarian cancer","volume":"40","author":"Shen","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jdermsci.2024.09.003_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljad032","article-title":"Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab","author":"Wu","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2024.09.003_bib25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.09.003_bib26","article-title":"Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata","author":"Renert-Yuval","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jdermsci.2024.09.003_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.19980","article-title":"Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study","author":"Chiricozzi","year":"2024","journal-title":"J Eur Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.jdermsci.2024.09.003_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/biom13040634","article-title":"Dupilumab in inflammatory skin diseases: a systematic review","volume":"13","author":"Olbrich","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.jdermsci.2024.09.003_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/all.15819","article-title":"Topical corticosteroids inhibit allergic skin inflammation but are ineffective in impeding the formation and expansion of resident memory T cells","volume":"79","author":"Ono","year":"2024","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.jdermsci.2024.09.003_bib30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2340\/00015555-2581","article-title":"Increased activity and apoptosis of eosinophils in blister fluids, skin and peripheral blood of patients with bullous pemphigoid","volume":"97","author":"Engmann","year":"2017","journal-title":"Acta Derm. Venereol."},{"issue":"1","key":"10.1016\/j.jdermsci.2024.09.003_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"11","key":"10.1016\/j.jdermsci.2024.09.003_bib32","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","article-title":"A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/nu mice","volume":"127","author":"Fairley","year":"2007","journal-title":"J. Invest Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2024.09.003_bib33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jid.2022.07.006","article-title":"Dipeptidyl Peptidase 4 Inhibitor-Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin","volume":"143","author":"Tuusa","year":"2023","journal-title":"J. Invest Dermatol."},{"issue":"11","key":"10.1016\/j.jdermsci.2024.09.003_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102661","article-title":"The role of T cells in pemphigus vulgaris and bullous pemphigoid","volume":"19","author":"Fang","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.jdermsci.2024.09.003_bib35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.clim.2006.03.014","article-title":"Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines","volume":"120","author":"Gounni Abdelilah","year":"2006","journal-title":"Clin. Immunol."},{"issue":"5","key":"10.1016\/j.jdermsci.2024.09.003_bib36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","article-title":"The chemokine superfamily revisited","volume":"36","author":"Zlotnik","year":"2012","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.jdermsci.2024.09.003_bib37","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2133.2008.08979.x","article-title":"CCL18 is expressed in patients with bullous pemphigoid and parallels disease course","volume":"160","author":"Gunther","year":"2009","journal-title":"Br. J. Dermatol."},{"issue":"11","key":"10.1016\/j.jdermsci.2024.09.003_bib38","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/all.13814","article-title":"Periostin: an emerging biomarker for allergic diseases","volume":"74","author":"Izuhara","year":"2019","journal-title":"Allergy"},{"issue":"7090","key":"10.1016\/j.jdermsci.2024.09.003_bib39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jdermsci.2024.09.003_bib40","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jid.2018.01.005","article-title":"Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models","volume":"138","author":"Sasaoka","year":"2018","journal-title":"J. Invest Dermatol."},{"issue":"6","key":"10.1016\/j.jdermsci.2024.09.003_bib41","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1046\/j.1365-2133.2000.03894.x","article-title":"High levels of interleukin-8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T-cell activities","volume":"143","author":"Sun","year":"2000","journal-title":"Br. J. Dermatol."},{"issue":"6591","key":"10.1016\/j.jdermsci.2024.09.003_bib42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/382501b0","article-title":"Biological activity of interleukin-16","volume":"382","author":"Cruikshank","year":"1996","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jdermsci.2024.09.003_bib43","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2249.2004.02570.x","article-title":"Interleukin-16 expression and release in bullous pemphigoid","volume":"137","author":"Frezzolini","year":"2004","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.jdermsci.2024.09.003_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jdermsci.2006.06.002","article-title":"Thymus and activation regulated chemokine (TARC)\/CCL17 and skin diseases","volume":"43","author":"Saeki","year":"2006","journal-title":"J. Dermatol. Sci."},{"issue":"2","key":"10.1016\/j.jdermsci.2024.09.003_bib45","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1111\/jdv.16851","article-title":"Serum thymus and activation-regulated chemokine (TARC\/CCL17) may be useful to predict the disease activity in patients with bullous pemphigoid","volume":"35","author":"Suzuki","year":"2021","journal-title":"J Eur Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.jdermsci.2024.09.003_bib46","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/jdv.12719","article-title":"Serum thymus and activation-regulated chemokine (TARC\/CCL17) levels reflect the disease activity in a patient with bullous pemphigoid","volume":"30","author":"Nin-Asai","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181124001919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181124001919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T19:03:40Z","timestamp":1748718220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181124001919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0923181124001919"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2024.09.003","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum inflammatory biomarkers associated with disease severity and response to dupilumab treatment in bullous pemphigoid: A cluster analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2024.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}